T-1095A
T-1095A is an investigational drug that was developed as a potential treatment for type 2 diabetes mellitus. It belongs to a class of drugs known as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), which work by preventing the reabsorption of glucose in the kidneys, thereby promoting its excretion in the urine.
Mechanism of Action[edit | edit source]
T-1095A functions by inhibiting the activity of the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubules of the kidneys. SGLT2 is responsible for the reabsorption of glucose from the glomerular filtrate back into the bloodstream. By inhibiting this transporter, T-1095A reduces the renal threshold for glucose, leading to increased urinary glucose excretion and a subsequent reduction in blood glucose levels.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of T-1095A includes its absorption, distribution, metabolism, and excretion characteristics. Upon oral administration, T-1095A is absorbed into the bloodstream, where it exerts its effects on the kidneys. The drug is metabolized primarily in the liver and is excreted through the urine.
Clinical Trials[edit | edit source]
T-1095A has undergone several clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. These studies have demonstrated that T-1095A effectively lowers blood glucose levels and has a favorable safety profile. However, as with other SGLT2 inhibitors, potential side effects include urinary tract infections and genital mycotic infections due to increased glucose in the urine.
Potential Benefits[edit | edit source]
The use of T-1095A in the management of type 2 diabetes offers several potential benefits:
- Improved glycemic control through a novel mechanism of action.
- Weight loss due to caloric loss via glucose excretion.
- Potential cardiovascular benefits, as observed with other SGLT2 inhibitors.
Side Effects and Considerations[edit | edit source]
While T-1095A is generally well-tolerated, it is important to consider potential side effects:
- Increased risk of urinary tract infections.
- Genital mycotic infections.
- Possible dehydration and electrolyte imbalances.
Also see[edit | edit source]
- Type 2 diabetes mellitus
- Sodium-glucose cotransporter 2 inhibitors
- Renal glucose reabsorption
- Diabetes management
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
